Revolution Medicines rises on daraxonrasib data that supports phase 3 program

2 hours ago 1

Revolution Medicines (NASDAQ:RVMD) said that new clinical results from several phase 1 clinical trials support moving daraxonrasib into a phase 3 program for first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
The company noted that the three-arm phase 3 trial would start